The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant

BackgroundHereditary angioedema due to the Thr328Lys variant in the coagulation factor XII (HAE-FXII) affects mainly women in whom the symptomatology is dependent on high estrogen levels. Clinical variability and incomplete penetrance are challenging features that hinder the diagnosis and management...

Full description

Bibliographic Details
Main Authors: Fernando Corvillo, María Eugenia de la Morena-Barrio, Carmen Marcos-Bravo, Margarita López-Trascasa, Vicente Vicente, Jonas Emsley, Teresa Caballero, Javier Corral, Alberto López-Lera
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fgene.2020.01033/full
id doaj-8c501be6821e43969c9be71be3b16b1b
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Fernando Corvillo
Fernando Corvillo
María Eugenia de la Morena-Barrio
María Eugenia de la Morena-Barrio
Carmen Marcos-Bravo
Margarita López-Trascasa
Margarita López-Trascasa
Vicente Vicente
Vicente Vicente
Jonas Emsley
Teresa Caballero
Teresa Caballero
Teresa Caballero
Javier Corral
Javier Corral
Alberto López-Lera
Alberto López-Lera
spellingShingle Fernando Corvillo
Fernando Corvillo
María Eugenia de la Morena-Barrio
María Eugenia de la Morena-Barrio
Carmen Marcos-Bravo
Margarita López-Trascasa
Margarita López-Trascasa
Vicente Vicente
Vicente Vicente
Jonas Emsley
Teresa Caballero
Teresa Caballero
Teresa Caballero
Javier Corral
Javier Corral
Alberto López-Lera
Alberto López-Lera
The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant
Frontiers in Genetics
hereditary angioedema
hereditary angioedema with normal C1-Inhibitor
hereditary angioedema due to FXII mutations
F12 gene
genetic disease-modifier
author_facet Fernando Corvillo
Fernando Corvillo
María Eugenia de la Morena-Barrio
María Eugenia de la Morena-Barrio
Carmen Marcos-Bravo
Margarita López-Trascasa
Margarita López-Trascasa
Vicente Vicente
Vicente Vicente
Jonas Emsley
Teresa Caballero
Teresa Caballero
Teresa Caballero
Javier Corral
Javier Corral
Alberto López-Lera
Alberto López-Lera
author_sort Fernando Corvillo
title The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant
title_short The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant
title_full The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant
title_fullStr The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant
title_full_unstemmed The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant
title_sort fxii c.-4t>c polymorphism as a disease modifier in patients with hereditary angioedema due to the fxii p.thr328lys variant
publisher Frontiers Media S.A.
series Frontiers in Genetics
issn 1664-8021
publishDate 2020-09-01
description BackgroundHereditary angioedema due to the Thr328Lys variant in the coagulation factor XII (HAE-FXII) affects mainly women in whom the symptomatology is dependent on high estrogen levels. Clinical variability and incomplete penetrance are challenging features that hinder the diagnosis and management of HAE-FXII. The c.-4T>C Kozak polymorphism is the only common variation accounting for FXII plasma levels and was previously shown to modify the course of HAE due to C1-Inhibitor deficiency.ObjectivesTo assess the influence of the c.-4T>C polymorphism on disease expression in 39 Spanish HAE-FXII index patients.MethodsThe c.-4T>C polymorphism was sequenced by the standard Sanger method, and HAE severity was calculated according to the score by Cumming et al. (2003) The activation of the contact system was quantified by the kallikrein-like activity of plasma in chromogenic assays upon activation with high-molecular-weight dextran sulfate.ResultsThe c.-4CC genotype was overrepresented in the studied cohort: 82% were CC-homozygous (expected frequency = 59%) and 18% were CT-heterozygous (expected frequency = 39%) (p = 0.001). Patients with a c.-4CC genotype exhibited higher kallikrein-like activity (0.9659 ± 0.1136) than those with a c.-4TC genotype (0.7645 ± 0.1235) (p = 0.024) or healthy donors. Moreover, the polymorphism influenced HAE-FXII severity score (c.-4CC = 4.43 ± 2.28 vs c.-4TC = 2.0 ± 1.15; p = 0.006) but not the degree of estrogen dependence or time until remission.ConclusionThe c.-4T>C polymorphism is overrepresented in a Spanish HAE-FXII cohort and significantly influences the degree of contact system activation and the clinical severity of the disease.
topic hereditary angioedema
hereditary angioedema with normal C1-Inhibitor
hereditary angioedema due to FXII mutations
F12 gene
genetic disease-modifier
url https://www.frontiersin.org/article/10.3389/fgene.2020.01033/full
work_keys_str_mv AT fernandocorvillo thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT fernandocorvillo thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT mariaeugeniadelamorenabarrio thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT mariaeugeniadelamorenabarrio thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT carmenmarcosbravo thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT margaritalopeztrascasa thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT margaritalopeztrascasa thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT vicentevicente thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT vicentevicente thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT jonasemsley thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT teresacaballero thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT teresacaballero thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT teresacaballero thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT javiercorral thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT javiercorral thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT albertolopezlera thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT albertolopezlera thefxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT fernandocorvillo fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT fernandocorvillo fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT mariaeugeniadelamorenabarrio fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT mariaeugeniadelamorenabarrio fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT carmenmarcosbravo fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT margaritalopeztrascasa fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT margaritalopeztrascasa fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT vicentevicente fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT vicentevicente fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT jonasemsley fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT teresacaballero fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT teresacaballero fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT teresacaballero fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT javiercorral fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT javiercorral fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT albertolopezlera fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
AT albertolopezlera fxiic4tcpolymorphismasadiseasemodifierinpatientswithhereditaryangioedemaduetothefxiipthr328lysvariant
_version_ 1724739053819002880
spelling doaj-8c501be6821e43969c9be71be3b16b1b2020-11-25T02:50:14ZengFrontiers Media S.A.Frontiers in Genetics1664-80212020-09-011110.3389/fgene.2020.01033550064The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys VariantFernando Corvillo0Fernando Corvillo1María Eugenia de la Morena-Barrio2María Eugenia de la Morena-Barrio3Carmen Marcos-Bravo4Margarita López-Trascasa5Margarita López-Trascasa6Vicente Vicente7Vicente Vicente8Jonas Emsley9Teresa Caballero10Teresa Caballero11Teresa Caballero12Javier Corral13Javier Corral14Alberto López-Lera15Alberto López-Lera16Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, SpainHospital La Paz Institute for Health Research (IdiPaz), Madrid, SpainCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, SpainHematology and Medical Oncology Department, University Hospital Morales Meseguer, Centro Regional de Hemodonación, University of Murcia, IMIB-Arrixaca, Murcia, SpainAllergy Department, University Hospital Complex of Vigo, Hospital Meixoeiro, Vigo, SpainHospital La Paz Institute for Health Research (IdiPaz), Madrid, SpainFaculty of Medicine, Autonomous University of Madrid, Madrid, SpainCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, SpainHematology and Medical Oncology Department, University Hospital Morales Meseguer, Centro Regional de Hemodonación, University of Murcia, IMIB-Arrixaca, Murcia, SpainCentre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, United KingdomCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, SpainHospital La Paz Institute for Health Research (IdiPaz), Madrid, SpainAllergy Department, La Paz University Hospital, Madrid, SpainCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, SpainHematology and Medical Oncology Department, University Hospital Morales Meseguer, Centro Regional de Hemodonación, University of Murcia, IMIB-Arrixaca, Murcia, SpainCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, SpainHospital La Paz Institute for Health Research (IdiPaz), Madrid, SpainBackgroundHereditary angioedema due to the Thr328Lys variant in the coagulation factor XII (HAE-FXII) affects mainly women in whom the symptomatology is dependent on high estrogen levels. Clinical variability and incomplete penetrance are challenging features that hinder the diagnosis and management of HAE-FXII. The c.-4T>C Kozak polymorphism is the only common variation accounting for FXII plasma levels and was previously shown to modify the course of HAE due to C1-Inhibitor deficiency.ObjectivesTo assess the influence of the c.-4T>C polymorphism on disease expression in 39 Spanish HAE-FXII index patients.MethodsThe c.-4T>C polymorphism was sequenced by the standard Sanger method, and HAE severity was calculated according to the score by Cumming et al. (2003) The activation of the contact system was quantified by the kallikrein-like activity of plasma in chromogenic assays upon activation with high-molecular-weight dextran sulfate.ResultsThe c.-4CC genotype was overrepresented in the studied cohort: 82% were CC-homozygous (expected frequency = 59%) and 18% were CT-heterozygous (expected frequency = 39%) (p = 0.001). Patients with a c.-4CC genotype exhibited higher kallikrein-like activity (0.9659 ± 0.1136) than those with a c.-4TC genotype (0.7645 ± 0.1235) (p = 0.024) or healthy donors. Moreover, the polymorphism influenced HAE-FXII severity score (c.-4CC = 4.43 ± 2.28 vs c.-4TC = 2.0 ± 1.15; p = 0.006) but not the degree of estrogen dependence or time until remission.ConclusionThe c.-4T>C polymorphism is overrepresented in a Spanish HAE-FXII cohort and significantly influences the degree of contact system activation and the clinical severity of the disease.https://www.frontiersin.org/article/10.3389/fgene.2020.01033/fullhereditary angioedemahereditary angioedema with normal C1-Inhibitorhereditary angioedema due to FXII mutationsF12 genegenetic disease-modifier